This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| sotalol | |
|---|---|
| Name | Sotalol |
| Tradename | Betapace, Sorine, others |
| Routes of administration | Oral, Intravenous |
| Class | Antiarrhythmic agent (Class III with nonselective beta blocker activity) |
| Legal US | Prescription only |
sotalol is an antiarrhythmic medication used to treat various cardiac rhythm disorders, principally ventricular and supraventricular arrhythmias. It combines beta-adrenergic blockade with action on cardiac repolarization, and is administered orally or intravenously under clinical monitoring. Major clinical guidelines and regulatory agencies recommend careful selection and monitoring because of risks including life-threatening proarrhythmia.
Sotalol is indicated for management of ventricular tachycardia, maintenance of sinus rhythm in atrial fibrillation or atrial flutter, and suppression of symptomatic ventricular ectopy in patients whose arrhythmias are life‑threatening or refractory to other therapy. Clinical practice recommendations from institutions such as the American Heart Association, European Society of Cardiology, and National Institute for Health and Care Excellence describe specific dosing and monitoring strategies. In acute care, sotalol intravenous infusion is used in monitored settings such as intensive care units and cardiac catheterization labs during electrophysiology procedures alongside therapies like cardioversion and radiofrequency ablation. Use is weighed against alternatives including amiodarone, flecainide, propafenone, and device therapies like the implantable cardioverter-defibrillator.
Sotalol exerts antiarrhythmic effects through dual actions: nonselective blockade of β1- and β2-adrenergic receptors and prolongation of cardiac action potential via inhibition of the rapid component of the delayed rectifier potassium current (IKr). These effects manifest as reduction in heart rate, decreased atrioventricular nodal conduction, and prolongation of the QT interval, which can suppress reentrant and focal arrhythmias but also predispose to torsades de pointes. Electrophysiology studies and textbooks reference interactions with ion channels and receptor pathways explored in laboratories associated with institutions like Johns Hopkins Hospital, Mayo Clinic, and Cleveland Clinic.
Sotalol is well absorbed after oral administration with bioavailability approaching 90–100%. It is minimally metabolized and is excreted largely unchanged by the kidneys; renal clearance correlates with creatinine clearance and dosing must be adjusted in renal impairment. Onset and half‑life parameters are detailed in pharmacology compendia from publishers such as Pharmacopoeia of the United States and professional resources at Massachusetts General Hospital and Brigham and Women's Hospital. Drug monitoring strategies align with recommendations from regulatory bodies like the Food and Drug Administration and European Medicines Agency.
Common adverse effects include bradycardia, fatigue, dizziness, and dyspnea, reflecting β‑blockade; less common but serious effects include bronchospasm, hypotension, heart block, and exacerbation of heart failure. A key risk is QT prolongation leading to torsades de pointes and sudden cardiac death, prompting inpatient initiation in many patients and ECG monitoring similar to protocols used for drugs discussed in reviews from Lancet, The New England Journal of Medicine, and Journal of the American College of Cardiology. Neuropsychiatric symptoms and hypoglycemia unawareness have been reported, aligning with adverse event surveillance by agencies like the World Health Organization.
Absolute contraindications include known hypersensitivity to the compound, sinus bradycardia, second- or third-degree atrioventricular block without pacemaker, and uncontrolled heart failure. Caution is advised in patients with asthma or chronic obstructive pulmonary disease, diabetes mellitus requiring insulin, and significant renal impairment; guidance is provided in position statements from organizations such as American College of Cardiology and European Medicines Agency. Pregnancy and lactation considerations are discussed in obstetric guidance from bodies like Royal College of Obstetricians and Gynaecologists.
Pharmacodynamic and pharmacokinetic interactions increase risk when sotalol is combined with other QT‑prolonging agents (for example, certain macrolide antibiotics like azithromycin and clarithromycin, antifungals such as ketoconazole, antipsychotics including haloperidol, and antiarrhythmics like dofetilide). Concomitant use with other β‑blockers, digoxin, or calcium channel blockers such as verapamil and diltiazem can potentiate bradycardia and conduction abnormalities; interactions are detailed in compendia used by hospitals like Cleveland Clinic and Mayo Clinic. Renal elimination creates interaction potential with agents that alter renal function, including nonsteroidal anti-inflammatory drugs and diuretics used in heart failure management.
Chemically, sotalol is a racemic mixture of D‑ and L‑enantiomers; the L‑enantiomer contributes predominantly to β‑adrenergic blocking activity while both enantiomers prolong cardiac repolarization. It is a sulfonamide derivative with the molecular framework described in pharmaceutical monographs and patents filed by manufacturers and researched at academic centers like University of California, San Francisco and Harvard Medical School. Formulations include immediate‑release oral tablets marketed under names such as Betapace and intravenous preparations for hospital use; packaging and regulatory labeling are overseen by agencies including the Food and Drug Administration.
Sotalol was developed in the 1970s and entered clinical use as interest in combined β‑blocker and potassium channel effects grew; its development and clinical adoption are recounted in reviews from journals like Circulation and historical summaries associated with institutions such as Duke University Hospital and Guy's and St Thomas' NHS Foundation Trust. Market availability and brand names have varied globally, with inclusion on formularies maintained by systems such as the National Health Service and procurement discussed in reports by the World Health Organization. Societal discussions about risk–benefit, monitoring burdens, and comparative effectiveness continue in forums such as guidelines from the American Heart Association and peer‑reviewed literature in The Lancet.
Category:Antiarrhythmic agents